trending Market Intelligence /marketintelligence/en/news-insights/trending/gws_rstkgczpjh2bbgfhxa2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Endologix gets US FDA warning on previously recalled heart products

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Endologix gets US FDA warning on previously recalled heart products

Endologix Inc. said the U.S. Food and Drug Administration determined that its AFX Strata heart devices, recalled in July, could lead to serious adverse health consequences or death.

The FDA issued a Class I recall, the most serious of the three class designations used to determine health hazard. The agency said the stent devices were associated with type 3 endoleaks, which are holes, defects or separations in the stent-graft material.

The Irvine, Calif.-based medical device maker noted that the recall did not apply to its AFX Duraply and AFX2 products because they use a different technology.

Endologix had requested all remaining AFX Strata devices be returned from the field and emphasized that it had not manufactured AFX Strata grafts since 2014.

In an Oct. 5 statement, Endologix CEO John Onopchenko said the AFX Strata product was removed from global inventory in the first half of 2017.